IP Library Granted Patent US 10,329,278
Granted Patent B2
US 10,329,278 · App. 16/010,831 · Granted Jun 25, 2019

Pharmaceutical compounds

Inventors: Giles Albert Brown (Cambridge, GB); Julie Elaine Cansfield (Cambridge, GB); Miles Stuart Congreve (Cambridge, GB); Benjamin Gerald Tehan (Cambridge, GB); Barry John Teobald (Cambridge, GB)
Assignee: Heptares Therapeutics Limited
C07D403/04A61P25/02A61P25/18A61P25/28C07D401/08C07D401/14C07D403/14C07D413/14C07D417/14C07D451/02C07D451/14C07D491/107C07D498/08
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,329,278
App. No.
16/010,831
Granted
Jun 25, 2019
Kind
B2
Abstract

This invention relates to compounds that are agonists of the muscarinic M 1 and/or M 4 receptor and which are useful in the treatment of diseases mediated by the muscarinic M 1 and M 4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula where X 1 ; X 2 ; R 1 and R 4 are as defined herein.

Claims (104)

1. A compound of the formula (1):

or a salt thereof, wherein:

X 1 and X 2 are saturated hydrocarbon groups which together contain a total of five to nine carbon atoms and zero or one oxygen atoms and which link together such that the moiety:

forms a monocyclic or bicyclic ring system optionally substituted with one or more fluorine atoms;

R 1 is selected from OR 5 ; NR 5 R 6 ; COR 5 ; COOR 5 ; CONR 5 R 6 ; CONR 5 OR 6 ; C(═NR 5 )R 6 ; C(═NOR 5 )R 6 ; OCOR 5 ; NR 7 COR 5 ; NR 7 CONR 5 R 6 ; NR 7 COOR 5 ; OCONR 5 R 6 ; CH 2 OR 5 ; CH 2 NR 5 R 6 ; CH 2 COR 5 ; CH 2 COOR 5 ; CH 2 CONR 5 R 6 ; CH 2 CONR 5 OR 6 ; CH 2 C(═NR 5 )R 6 ; CH 2 C(═NOR 5 )R 6 ; CH 2 OCOR 5 ; CH 2 NR 7 COR 5 ; CH 2 NR 7 CONR 5 R 6 ; CH 2 NR 7 COOR 5 ; CH 2 OCONR 5 R 6 ; a C 1-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidized forms thereof; and an optionally substituted 4, 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof;

R 4 is H or a C 1-6 non-aromatic hydrocarbon group which is optionally substituted with one to six fluorine atoms and wherein one or two, but not all, carbon atoms of the hydrocarbon group may optionally be replaced by a heteroatom selected from O, N and S and oxidised forms thereof; and

R 5 , R 6 and R 7 are the same or different and each is independently selected from hydrogen, a non-aromatic C 1-6 hydrocarbon group optionally substituted with one or more fluorine atoms or optionally substituted with a 4, 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof, or R 5 and R 6 can be joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

2. The compound according to claim 1 wherein R 1 is selected from OR 5 ; NR 5 R 6 ; COOR 5 ; CONR 5 R 6 ; CONR 5 OR 6 ; C(═NOR 5 )R 6 ; CH 2 NR 7 COR 5 ; a C 1-3 alkyl group which is optionally substituted with one to three fluorine atoms; and an optionally substituted 4, 5- or 6-membered ring containing 1, or 2 heteroatoms selected from O, N and S and oxidized forms thereof.

3. The compound according to claim 1 wherein R 1 is selected from COOR 5 ; CONR 5 R 6 ; CONR 5 OR 6 ; C(═NOR 5 )R 6 ; and an optionally substituted 5-membered ring containing 1, or 2 hetero atoms selected from O, N and S and oxidized forms thereof.

4. The compound according to claim 1 wherein R 1 is selected from COOR 5 and CONR 5 R 6 .

5. The compound according to claim 1 wherein R 5 is selected from hydrogen, a non-aromatic C 1-6 hydrocarbon group optionally substituted with one or more fluorine atoms or optionally substituted with a 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof, or R 5 and R 6 can be joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 hetero atoms selected from O, N and S and oxidized forms thereof.

6. The compound according to claim 1 wherein R 6 is selected from hydrogen, a non-aromatic C 1-6 hydrocarbon group optionally substituted with one or more fluorine atoms or optionally substituted with a 4, 5- or 6-membered ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof, or R 5 and R 6 can be joined together to form an optionally substituted monocyclic or bicyclic ring containing 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

7. The compound according to claim 1 wherein R 1 is COOR 5 wherein R 5 is a non-aromatic C 1-6 hydrocarbon group or R 1 is CONR 5 R 6 wherein R 5 is a non-aromatic C 1-6 hydrocarbon group and R 6 is selected from hydrogen and a non-aromatic C 1-6 hydrocarbon group, or R 1 is CONR 5 R 6 and R 5 and R 6 are joined together to form an optionally substituted monocyclic or bicyclic ring containing, 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof, or R 1 is CONR 5 OR 6 wherein R 5 is a non-aromatic C 1-6 hydrocarbon group and R 6 is a non-aromatic C 1-6 hydrocarbon group.

8. The compound according to claim 1 wherein R 1 is selected from NR 5 R 6 ; CONR 5 R 6 ; and CH 2 NR 5 R 6 ; and R 5 and R 6 are joined together to form an optionally substituted monocyclic or bicyclic ring containing. 0, 1, 2 or 3 heteroatoms selected from O, N and S and oxidized forms thereof.

9. The compound according to claim 1 wherein R 1 is selected from the group consisting of:

10. The compound according to claim 1 wherein R 4 is selected from the group consisting of H, methyl, ethyl, ethynyl and 1-propynyl.

11. The compound according to claim 1 wherein the bicyclic ring system formed by the moiety:

is selected from ring systems below:

12. The compound according to claim 1 of the formula (2):

wherein n is 1 or 2.

13. The compound according to claim 1 wherein the compound is selected from the group consisting of:

ethyl 6-[(1R,5S,6r)-6-(ethoxycarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.3]heptane-2-carboxylate;

ethyl 6-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.3]heptane-2-carboxylate;

ethyl 6-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-2-azaspiro[3.3]heptane-2-carboxylate;

ethyl 6-[(1R,5S,6r)-6-(2-methyl-1,3-thiazol-4-yl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.3]heptane-2-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(ethoxycarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[(2-methylpropyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[(cyclobutylmethyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[(1-methylcyclobutyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[ethyl(methyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

methyl 2-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[methyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

methyl 2-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[cyclopropyl(ethyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(pyrrolidin-l-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(piperidin-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-{[(2R)-2-methylpiperidin- 1-yl]carbonyl}-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-{[(2S)-2-methylpiperidin-1-yl]carbonyl}-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(azepan-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(1,4-oxazepan-4-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(2-azaspiro[3.3]hept-2-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(4-azaspiro[2.3]hex-4-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(1-azaspiro[3.3]hept-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

methyl 2-[(1R,5S,6r)-6-(1-azaspiro[3.3]hept-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(6-oxa-1-azaspiro[3.3]hept-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[methoxy(methyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6r)-6-[ethyl(methoxy)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(N-methoxypropanimidoyl)-3-azabicyclo[3.1.0]hexan-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[6-(trifluoromethyl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-{(1R,5S,6s)-6-[ethyl(2,2,2-trifluoroethyl)amino]-3-azabicyclo[3.1.0]hexan-3-yl}-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6s)-6-(1-phenylethoxy)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(1-methyl-1H-pyrazol-5-yl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 2-[(1R,5S,6r)-6-(2-methyl-1,3-thiazol-4-yl)-3-azabicyclo[3.1.0]hex-3-yl]-6-azaspiro[3.4]octane-6-carboxylate;

ethyl 6-[(1R,5S,6r)-6-(ethoxycarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.4]octane-2-carboxylate;

ethyl 6-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.4]octane-2-carboxylate;

methyl 6-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.4]octane-2-carboxylate;

ethyl 6-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-2-azaspiro[3.4]octane-2-carboxylate;

ethyl 4-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]piperidine-1-carboxylate;

ethyl 6-[(1R,5S,6r)-6-(ethoxycarbonyl)-3-azabicyclo[3.1.0]hexan-3-yl]-3-azabicyclo[3.1.1]heptane-3-carboxylate;

ethyl 6-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]-3-azabicyclo[3.1.1]heptane-3-carboxylate;

ethyl 8-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]-3-azabicyclo[3.2.1]octane-3-carboxylate;

ethyl 3-[(1R,5S,6r)-6-(ethoxycarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate;

ethyl 3-{(1R,5S,6r)-6-[ethyl(methyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-8-azabicyclo[3.2.1]octane-8-carboxylate;

ethyl 3-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate;

ethyl 3-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-8-azabicyclo[3.2.1]octane-8-carboxylate;

ethyl 3-[(1R,5S ,6r)-6-{[acetyl(ethyl)amino]methyl}-3-azabicyclo[3.1.0]hex-3-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate;

ethyl 3-[(1R,5S,6r)-6-(2-methyl-1,3-thiazol-4-yl)-3-azabicyclo[3.1.0]hex-3-yl]-8-azabicyclo[3.2.1]octane-8-carboxylate;

ethyl 5-[(1R,5S,6r)-6-(ethoxycarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl (1S,4S)-5-{(1R,5S,6r)-6-[ethyl(methyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl (1R,4R)-5-{(1R,5S,6r)-6-[ethyl(methyl)carbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl}-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl (1S,4S)-5-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl (1R,4R)-5-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate;

methyl 5-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl 5-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl (1S,4S)-5-{(1R,5S,6r)-6-[cyclopropyl(ethyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl 5-{(1R,5S,6r)-6-[methoxy(methyl)carbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl}-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl 5-{(1R,5S,6r)-6-[ethyl(methoxy)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-2-azabicyclo[2.2.2]octane-2-carboxylate;

ethyl 3-{(1R,5S ,6r)-6-[ethyl(methyl)carbamoyl]-3 -azabicyclo[3.1.0]hex-3-yl}-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 3-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-9-azabicyclo[3.3.1]nonane-9-carboxylate;

methyl 3-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-{(1R,5S ,6r)-6-[ethyl(methyl)carbamoyl]-3-azabicyclo[3.1.0]hex-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

methyl 7-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-{(1R,5S,6r)-6-[methyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

methyl 7-((1R,5S ,6r)-6-(isopropyl(methyl)carbamoyl)-3 -azabicyclo[3.1.0]hexan-3-yl)-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-{(1R,5S ,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3 -azabicyclo[3.1.0]hex-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

methyl 7-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-{(1R,5S,6r)-6-[cyclopropyl(methyl)carbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-{(1R,5S ,6r)-6-[cyclopropyl(ethyl)carbamoyl] -3-azabicyclo[3.1.0]hex-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

methyl 7-{(1R,5S,6r)-6-[cyclopropyl(ethyl)carbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-[(1R,5S,6r)-6-(piperidin-l-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

methyl 7-[(1R,5S,6r)-6-(piperidine-l-carbonyl)-3-azabicyclo[3.1.0]hexan-3-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-[(1R,5S,6r)-6-(morpholine-4-carbonyl)-3-azabicyclo[3.1.0]hexan-3-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-[(1R,5S,6r)-6-(azepan-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 7-[(1R,5S,6r)-6-(1-azaspiro[3.3]hept-1-ylcarbonyl)-3-azabicyclo[3.1.0]hex-3-yl]-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate;

ethyl 4-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]azepane-1-carboxylate;

ethyl 3-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]-6-azabicyclo[3.2.1]octane-6-carboxylate; and

ethyl 5-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hexan-3-yl]hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate, or salts thereof.

14. A pharmaceutical composition comprising a compound as defined in claim 1 and a pharmaceutically acceptable excipient.

15. The compound according to claim 13 which is methyl 6-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.4]octane-2-carboxylate or a salt thereof.

16. The compound according to claim 13 which is ethyl 6-[(1R,5S,6r)-6-(diethylcarbamoyl)-3-azabicyclo[3.1.0]hex-3-yl]-2-azaspiro[3.4]octane-2-carboxylate or a salt thereof.

17. The compound according to claim 13 which is methyl 7-{(1R,5S,6r)-6-[ethyl(propan-2-yl)carbamoyl]-3-azabicyclo[3.1.0]hexan-3-yl}-3-oxa-9-azabicyclo[3.3.1]nonane-9-carboxylate or a salt thereof.

Assignments (3)
CHANGE OF NAME Recorded Sep 9, 2024
From: HEPTARES THERAPEUTICS LIMITED
To: NXERA PHARMA UK LIMITED
Reel/Frame 068524/0400 →
CHANGE OF ADDRESS Recorded Mar 21, 2019
From: HEPTARES THERAPEUTICS LIMITED
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 048661/0096 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 25, 2018
From: BROWN, GILES ALBERT; CANSFIELD, JULIE ELAINE; CONGREVE, MILES STUART; TEHAN, BENJAMIN GERALD; TEOBALD, BARRY JOHN
To: HEPTARES THERAPEUTICS LIMITED
Reel/Frame 046626/0820 →
Priority Claims (1)
GB 1709652.0 · Jun 16, 2017 · national
Continuity (1)
Related Publication 20180362507A1 · Dec 20, 2018
Cited By (3)
US 12,202,843 US 12,215,099 US 12,291,512